Crestor vs Leqvio: What to Do When One Fails

How These Two Drugs Actually Work

Rosuvastatin and inclisiran share one goal (lowering LDL-C) but operate at entirely different points in cholesterol biology. Understanding that distinction is what makes the "failure" question answerable.

Rosuvastatin: Upstream Enzyme Inhibition

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Less intracellular cholesterol prompts the liver to upregulate LDL receptors, pulling more LDL-C out of circulation. High-intensity dosing (20 to 40 mg daily) reduces LDL-C by roughly 50 to 55% from baseline in most patients. The JUPITER trial (N=17,802) confirmed a 44% relative risk reduction in major cardiovascular events with rosuvastatin 20 mg vs. Placebo over a median 1.9 years.

Rosuvastatin requires daily adherence. Miss doses and the enzyme rebounds within 24 to 48 hours, erasing progress. That pharmacokinetic reality is one of the most common reasons it "fails" in clinical practice.

Inclisiran: Downstream Gene Silencing

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 mRNA inside hepatocytes. PCSK9 normally marks LDL receptors for degradation; silencing its production leaves more receptors on the cell surface to clear LDL-C from the bloodstream. The effect persists for approximately six months per injection, which is why the FDA-approved labeling specifies dosing at Day 1, Day 90, and then every 6 months.

Because the gene-silencing effect is durable, missed daily pills are irrelevant. A patient who cannot tolerate daily medication or who has low adherence may respond far better to a twice-yearly clinic injection.

When Rosuvastatin Fails: Four Distinct Scenarios

"Rosuvastatin failure" is not a single clinical event. Each scenario points toward a different next step, and inclisiran fits some better than others.

Scenario 1: Myopathy or Statin Intolerance

Between 5 and 10% of patients on statins discontinue because of muscle-related symptoms, according to a 2018 meta-analysis published in JAMA. Confirmed statin intolerance is the clearest indication to switch to a non-statin agent. Inclisiran, which has no skeletal-muscle mechanism, did not show myopathy signal in ORION-10 or ORION-11; adverse events in both trials were comparable to placebo for musculoskeletal complaints. Patients who cannot tolerate any dose of rosuvastatin are reasonable candidates for inclisiran monotherapy.

A word on the ORION-10 data: in statin-intolerant sub-populations studied as part of the ORION-9 trial (N=482), inclisiran reduced LDL-C by 39.7% vs. A 1.0% increase with placebo at Month 17 (P<0.001). (PubMed: ORION-9)

Scenario 2: Insufficient LDL-C Reduction at Maximum Tolerated Dose

Some patients on rosuvastatin 40 mg still do not reach their guideline-recommended LDL-C target. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, cited in the AHA Scientific Statements portal, recommends adding a non-statin agent when LDL-C remains above 70 mg/dL (1.8 mmol/L) in very high-risk ASCVD patients despite maximally tolerated statin therapy. Inclisiran added on top of rosuvastatin is additive: ORION-11 enrolled patients already on statin therapy and found a time-averaged LDL-C reduction of 50% from baseline with inclisiran vs. 1% with placebo over 17 months.

Scenario 3: Non-Adherence to Daily Oral Therapy

Daily pill burden contributes to treatment dropout. A 2020 analysis in BMJ Open found that approximately 50% of patients prescribed a statin had stopped taking it within 12 months of initiation. Switching to a twice-yearly subcutaneous injection removes the daily decision entirely. The injection is administered in-office, creating a structured touchpoint that also supports cardiovascular risk-factor review.

Scenario 4: Hepatic Enzyme Elevation on Rosuvastatin

Mild transaminase elevations occur in fewer than 1% of statin-treated patients, but when they persist above three times the upper limit of normal, guidelines recommend stopping the statin. Inclisiran does not share the hepatotoxicity mechanism; its FDA prescribing information does not list hepatic enzyme elevation as a dose-limiting concern.

When Inclisiran Fails: What to Try Next

Inclisiran failure is less common but does occur. The two main reasons are inadequate response and access or insurance denial.

Inadequate LDL-C Response

Roughly 10 to 15% of patients in ORION-10 and ORION-11 did not achieve the expected 50% LDL-C reduction. Genetic heterozygous or homozygous familial hypercholesterolemia (HeFH or HoFH) may blunt the PCSK9-pathway response because some HoFH patients have near-zero functional LDL receptors regardless of PCSK9 levels. The FH Foundation clinical guidance recommends LDL apheresis or lomitapide in HoFH when PCSK9-pathway agents are insufficient.

For patients with partial response, adding or reintroducing a maximally tolerated statin dose (even rosuvastatin 5 to 10 mg in a partially intolerant patient) can provide an additional 20 to 30% reduction on top of inclisiran's 50%, as both mechanisms are pharmacologically independent.

Coverage Denial or Access Barriers

Inclisiran's wholesale acquisition cost (approximately $3,500 per dose in the US as of 2024) means payer prior-authorization denial is common. When inclisiran is not accessible, PCSK9 monoclonal antibodies (evolocumab, alirocumab) provide a mechanistically similar PCSK9 blockade at a different price point, with established cardiovascular outcome data from FOURIER (PubMed) and ODYSSEY OUTCOMES (PubMed). Ezetimibe 10 mg daily is a lower-cost oral add-on that reduces LDL-C by an additional 18 to 20% via intestinal cholesterol absorption inhibition (NEJM, IMPROVE-IT trial).

Key Trial Data: Side-by-Side

Comparing the two drugs' evidence bases requires honest acknowledgment that they were studied in partly different populations.

JUPITER (Rosuvastatin)

The JUPITER trial enrolled 17,802 adults with LDL-C below 130 mg/dL but elevated hsCRP. Rosuvastatin 20 mg reduced LDL-C by 50% and cut the primary composite cardiovascular endpoint by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) vs. Placebo. The trial was stopped early at a median 1.9 years due to overwhelming efficacy. New-onset diabetes was higher in the rosuvastatin arm (3.0% vs. 2.4%), a signal that has been reproduced across statin meta-analyses.

ORION-10 and ORION-11 (Inclisiran)

ORION-10 enrolled 1,561 patients with ASCVD already on maximally tolerated statin therapy; ORION-11 enrolled 1,617 patients with ASCVD or ASCVD-risk equivalents, also on statins. Inclisiran 284 mg reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 at Day 510 vs. Placebo (both P<0.001). Injection-site reactions occurred in 2.6 to 4.7% of inclisiran patients vs. 0.9% with placebo. No signal for myopathy, hepatotoxicity, or new-onset diabetes emerged in either trial.

Cardiovascular outcomes data for inclisiran are expected from the ORION-4 trial (N=15,000, estimated completion 2026), registered at ClinicalTrials.gov / NCT03705234. Rosuvastatin currently holds the stronger outcomes pedigree.

Combination Therapy: Using Both Together

Rosuvastatin plus inclisiran is not just acceptable; it is the preferred strategy in very high-risk patients who cannot reach LDL-C targets on either agent alone.

Mechanism Rationale

HMG-CoA inhibition (rosuvastatin) and PCSK9 mRNA silencing (inclisiran) act on separate pathways. Rosuvastatin upregulates LDL receptor expression by reducing intracellular cholesterol; inclisiran prevents the degradation of those same receptors by silencing PCSK9. The combination produces more receptors (rosuvastatin effect) that survive longer (inclisiran effect). This pharmacological independence underlies the additive LDL-C reductions seen in ORION-10 and ORION-11, where approximately 90% of participants were already on statin background therapy.

Practical Targets for Combination Use

The 2023 ESC/EAS Guidelines on Dyslipidaemia, summarized in European Heart Journal, recommend an LDL-C target below 55 mg/dL (1.4 mmol/L) for very high-risk patients, and below 40 mg/dL (1.0 mmol/L) for those with a second cardiovascular event within two years. Achieving 40 mg/dL requires approximately 65 to 70% LDL-C reduction from an untreated baseline of 120 mg/dL. That reduction is not reliably achievable with rosuvastatin alone (50 to 55%) but becomes reachable when inclisiran adds its ~50% on top.

Safety of Very Low LDL-C

A concern sometimes raised: is LDL-C below 40 mg/dL safe? The FOURIER trial (evolocumab plus statin) achieved median on-treatment LDL-C of 30 mg/dL with no excess risk of adverse neurological, hormonal, or hemorrhagic events over 2.2 years follow-up (PubMed). The ACC Expert Consensus Decision Pathway states that "no lower threshold for LDL-C has been established below which harm occurs."

Deciding Between Switch vs. Add-On: A Clinical Framework

The decision to switch from rosuvastatin to inclisiran versus adding inclisiran on top of rosuvastatin depends on three variables: the reason for failure, the patient's current LDL-C level, and whether any statin dose is tolerated at all.

Switch (rosuvastatin OUT, inclisiran IN):

• Complete statin intolerance with confirmed myopathy or rhabdomyolysis
• Persistent hepatic enzyme elevation above 3x ULN on any statin dose
• Patient unable or unwilling to take any daily oral medication

Add-On (rosuvastatin stays, inclisiran added):

• LDL-C remains above target despite maximum tolerated rosuvastatin dose
• High-risk ASCVD patient with recurrent cardiovascular events
• HeFH patient not at guideline-specified LDL-C goal

Consider alternatives before adding inclisiran:

• Ezetimibe 10 mg daily as a lower-cost first add-on step (18 to 20% additional LDL-C reduction, IMPROVE-IT)
• Bempedoic acid 180 mg daily if ezetimibe is insufficient (additional 18%, CLEAR Harmony trial)

Monitoring After Switching or Adding Inclisiran

What Monitoring Is Required

After starting inclisiran, no lipid panel adjustment between scheduled injections is needed for dose titration because the dose does not change regardless of LDL-C response. The FDA label does not specify routine labs during treatment, though most clinical programs obtain a fasting lipid panel at Month 3 (just before the second injection) to confirm response and document the pre-injection trough level.

Baseline hepatic function testing is standard before any new lipid-lowering agent. Renal impairment does not require dose adjustment for inclisiran, per prescribing information.

Expected LDL-C Timeline

LDL-C begins falling within two weeks of the first inclisiran injection. The nadir occurs at approximately Day 60, then rises modestly before the Day 90 second injection resets it. By Day 150, the time-averaged LDL-C reduction stabilizes at the approximately 50% figure seen across ORION trials. Patients and prescribers should be counseled that a lipid panel drawn at Day 180 (immediately before the next injection) will show a slightly higher LDL-C than the nadir; this does not indicate treatment failure.

Cost, Insurance, and Access Considerations

Rosuvastatin 40 mg generic costs under $15 per month in most US pharmacies. Inclisiran's list price of approximately $3,500 per injection (two injections per year) means a gross annual cost near $7,000 before rebates or patient assistance. Novartis operates the Leqvio patient assistance program; income-eligible patients may qualify for $0 co-pay. Prior authorization for inclisiran typically requires documentation of statin intolerance or failure to reach LDL-C goal on maximally tolerated statin plus ezetimibe, consistent with ACC guidance on non-statin therapies.

For practices managing large ASCVD populations, the CDC's Million Hearts initiative supports protocol-driven lipid management that includes non-statin therapies in appropriate patients, which can help document medical necessity for payer approval.

Special Populations

Patients with Type 2 Diabetes

Rosuvastatin modestly raises fasting glucose and HbA1c. The JUPITER trial found a hazard ratio for new-onset diabetes of 1.25 (95% CI 1.05 to 1.49) with rosuvastatin 20 mg, as analyzed in the original NEJM publication. Inclisiran showed no glycemic signal in ORION-10 or ORION-11. For a patient with pre-diabetes and borderline LDL-C control, the glycemic neutrality of inclisiran is a genuine clinical advantage worth weighing.

Chronic Kidney Disease

Both drugs are used in CKD. Rosuvastatin clearance is partly renal; doses above 10 mg daily are not recommended in patients with eGFR below 30 mL/min/1.73m2, per FDA prescribing information. Inclisiran does not require dose adjustment in any stage of CKD, broadening its utility in patients with advanced renal disease where high-dose statins are limited.

Older Adults

Statin-associated myopathy risk increases with age, particularly above 75 years. A 2021 review in JAMA Internal Medicine noted that adults over 75 without established ASCVD may derive less absolute benefit from statin therapy. For an older patient with established ASCVD who cannot tolerate rosuvastatin, inclisiran's twice-yearly injection schedule removes the daily pill burden and reduces fall-risk polypharmacy concerns, though the cardiovascular outcome data from ORION-4 are still pending.

What Prescribers and Patients Often Get Wrong

Switching from rosuvastatin to inclisiran is not appropriate simply because a patient's LDL-C is "not responding fast enough." Inclisiran takes the same 6 to 8 weeks to show its maximal single-injection effect as any other LDL-lowering agent. Premature switches based on a four-week lipid panel misread normal pharmacokinetics as failure.

Prescribers also sometimes conflate statin intolerance with patient preference for not taking a statin. Confirmed intolerance requires documentation of muscle symptoms with creatine kinase elevation or symptoms that resolve on discontinuation and recur on re-challenge, as defined in European Heart Journal guidance. Without that documentation, payer approval for inclisiran as a statin replacement (rather than add-on) is unlikely.

Patients frequently ask whether inclisiran injections hurt. Injection-site adverse events in ORION-10 were mild-to-moderate in all cases and resolved without treatment. None resulted in discontinuation in the trial population.